Pharmacological treatment of unipolar depressive disorders: summary of WFSBP guidelines

被引:107
|
作者
Bauer, Michael [1 ]
Severus, Emanuel [1 ]
Moller, Hans-Jurgen [2 ]
Young, Allan H. [3 ]
机构
[1] Tech Univ Dresden, Univ Hosp Carl Gustav Carus, Dept Psychiat & Psychotherapy, Fetscherstr 74, D-01307 Dresden, Germany
[2] Ludwig Maximilians Univ Munchen, Dept Psychiat, Munich, Germany
[3] Kings Coll London, Inst Psychiat Psychol & Neurosci, Dept Psychol Med, London, England
关键词
Primary care; major depressive disorder; pharmacotherapy; guidelines; CONTINUATION TREATMENT; BIOLOGICAL TREATMENT; CONTROLLED-TRIALS; MAJOR DEPRESSION; WORLD FEDERATION; DOUBLE-BLIND; ANTIDEPRESSANTS; METAANALYSIS; UPDATE; MANAGEMENT;
D O I
10.1080/13651501.2017.1306082
中图分类号
R749 [精神病学];
学科分类号
100205 ;
摘要
Objective: Major depressive disorder (MDD) is a severe mood disorder affecting individuals of all ages and is characterised by single or recurrent major depressive episodes. Key elements of acute and maintenance treatment of MDD include pharmacotherapy, and psychological approaches such as psychoeducation and adherence monitoring.Methods: This summary of the Practice guidelines for the biological treatment of unipolar depressive disorders' comprises acute, continuation and maintenance treatment developed by an international Task Force of the World Federation of Societies of Biological Psychiatry (WFSBP), and focuses on pharmacological treatment options.Results: A variety of different antidepressants are available for the effective acute and prophylactic treatment of depressed patients. Randomised placebo-controlled efficacy studies indicate that all major classes of antidepressants are effective in acute treatment but also in preventing recurrence of depression showing about a two-fold higher relapse rate with placebo treatment. Evidence suggests that the newer' antidepressants have superior long-term effectiveness due to better tolerability and safety profile compared to traditional antidepressants, e.g., the tricyclic antidepressants (TCA).Conclusions: Despite progress in the availability of different treatment options there is still a substantial proportion of patients who do not achieve full remission. Several add-on pharmacological treatment options are among the best-evidenced strategies for refractory depressed patients.
引用
收藏
页码:166 / 176
页数:11
相关论文
共 50 条
  • [31] Clinical and demographic predictors of response to rTMS treatment in unipolar and bipolar depressive disorders
    Rostami, Reza
    Kazemi, Reza
    Nitsche, Michael A.
    Gholipour, Fatemeh
    Salehinejad, M. A.
    CLINICAL NEUROPHYSIOLOGY, 2017, 128 (10) : 1961 - 1970
  • [32] The clinical course of unipolar major depressive disorders
    Judd, LL
    ARCHIVES OF GENERAL PSYCHIATRY, 1997, 54 (11) : 989 - 991
  • [33] Unipolar depressive disorders have a common genotype
    Edvardsen, Jack
    Torgersen, Svenn
    Roysamb, Espen
    Lygren, Sissel
    Skre, Ingunn
    Onstad, Sidsel
    Oien, Per Anders
    JOURNAL OF AFFECTIVE DISORDERS, 2009, 117 (1-2) : 30 - 41
  • [34] The World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Biological Treatment of Bipolar Disorders: Update 2009 on the Treatment of Acute Mania
    Grunze, Heinz
    Vieta, Eduard
    Goodwin, Guy M.
    Bowden, Charles
    Licht, Rasmus W.
    Moeller, Hans-Juergen
    Kasper, Siegfried
    WORLD JOURNAL OF BIOLOGICAL PSYCHIATRY, 2009, 10 (02): : 85 - 116
  • [35] Neurocognitive profile of outpatients with unipolar depressive disorders
    Schwert, Christine
    Stohrer, Maren
    Aschenbrenner, Steffen
    Weisbrod, Matthias
    Schroeder, Annette
    JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY, 2019, 41 (09) : 913 - 924
  • [36] WFSBP and IAWMH Guidelines for the treatment of alcohol use disorders in pregnant women (vol 20, pg 17, 2019)
    Thibaut, F.
    Chagraoui, A.
    Buckley, L.
    Gressier, F.
    Labad, J.
    Lamy, S.
    Potenza, M. N.
    Kornstein, S. G.
    Rondon, M.
    Riecher-Rossler, A.
    Soyka, M.
    Yonkers, K.
    WORLD JOURNAL OF BIOLOGICAL PSYCHIATRY, 2020, 21 (08): : 658 - 658
  • [37] Clinical guidelines for the treatment of depressive disorders VII. Comorbidity
    Enns, MW
    Swenson, JR
    McIntyre, RS
    Swinson, RP
    Kennedy, SH
    CANADIAN JOURNAL OF PSYCHIATRY-REVUE CANADIENNE DE PSYCHIATRIE, 2001, 46 : 77S - 90S
  • [38] Analysis and evaluation of current guidelines for diagnosis and treatment of depressive disorders
    Härter, M
    Bermejo, I
    Aschenbrenner, A
    Berger, M
    FORTSCHRITTE DER NEUROLOGIE PSYCHIATRIE, 2001, 69 (09) : 390 - +
  • [39] Guidelines and the psychology of medical decision making in the treatment of depressive disorders
    Linden, M
    FORTSCHRITTE DER NEUROLOGIE PSYCHIATRIE, 2005, 73 (05) : 249 - 258
  • [40] Clinical guidelines for the treatment of depressive disorders III. Psychotherapy
    Segal, ZV
    Whitney, DK
    Lam, RW
    CANADIAN JOURNAL OF PSYCHIATRY-REVUE CANADIENNE DE PSYCHIATRIE, 2001, 46 : 29S - 37S